Obiettivo
Efficient and safe vectors for gene therapy of prostate and bladder cancer will be developed by modification of viruses with multivalent hydrophilic polymers. This approach is particularly powerful because it permits complete shielding of viral tropism without genetic engineering. The resulting vectors are less immunogenicthan normal viruses and will be targeted to tumour cell-surface receptors. Their infectivity of these vectors is not affected by neutralising antibodies in serum, a major limitation of current use of viruses for gene delivery - particularly in the clinics. Viruses retargeted in this way operate at a lower MOI than regular viruses in serum and maintain extremely high efficiency of gene expression. These vectors should provide an effective means to realise the substantial promise of gene therapy, and this proposal combines cell/molecular biology and virology with polymer chemistry in their development.
Campo scientifico
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesclinical medicineoncologybladder cancer
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- natural sciencesbiological sciencesmicrobiologyvirology
- natural scienceschemical sciencespolymer sciences
Invito a presentare proposte
Data not availableMeccanismo di finanziamento
CSC - Cost-sharing contractsCoordinatore
OX2 6he OXFORD
Regno Unito